An interventional study of IASD System in Heart Failure, sponsored by Corvia Medical. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-07-15.
Sponsored by Corvia Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Heart Failure with a site in Australia — 25 open to participants now, 41 under way, 9 of them phase 3. Heart Failure · Australia.
Among the 167 studies in Heart Failure with a site in Australia, this one is the 124th largest by enrollment of the 135 interventional ones that give a count, is one of 10 that started in 2012, is one of 57 with no phase, and was the 53rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →25 of the 167 studies in Heart Failure with a site in Australia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, United States, Argentina and 29 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Australia, Austria, Czechia and 10 more countries
Ages 18+
Novo Nordisk A/S · Sites in Australia, United States, Argentina and 24 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Australia, Bulgaria, Croatia and 4 more countries
Ages 18+
EBR Systems, Inc. · Sites in Australia
Ages 22+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 26 · Phase 3 47 · Phase 4 8
First in 1983; this study’s year is marked. 10 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 350 across the 135 interventional studies, 608 across the 31 observational. Of the 116 that completed or were terminated, 59 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 167 have an industry lead sponsor. The 10 most frequent:
Corvia Medical is the lead sponsor of 8 studies on the registry; none are open to participants now.
Corvia Medical has 8 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
10 of the studies in Heart Failure with a site in Australia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT04536870Monash UniversityStatins in Reducing Events in the Elderly (STAREE) Heart Sub-study | 2026-12 |
| NCT03093961Corvia MedicalREDUCE LAP-HFREF TRIAL | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 167 studies in Heart Failure with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and potential benefits of the interatrial septal defect (IASD) System in patients with heart failure with preserved ejection fraction.
The study was a multi-center, non-randomized feasibility evaluation of the IASD System at three centers in three countries (Denmark, Australia, and Czech Republic). Relevant ethics committee and competent authority approvals were obtained. The study was conducted in accordance with the Declaration of Helsinki. The protocol required the treatment of a minimum of 5 patients, and allowed up to twenty patients to be enrolled.
The primary objective of the trial was to evaluate the safety and potential benefits of the IASD Device System in the treatment of patients with symptomatic heart failure with preserved ejection fraction, despite optimal medical management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects are implanted with the study device.
Device: IASD System
Implantation of the DC Devices Inc. IASD System
Serious Adverse Device Events
Time frame: One month
The record gives a start of May 2012, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Corvia Medical